Breast ReconstructionOPBC-02PREPECNCT04293146
Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy OPBC-02PREPEC
A study testing pre-pectoral IBBR and sub-pectoral IBBR in people with Breast Reconstruction and Implant-Based Breast Reconstruction (IBBR), run by University Hospital, Basel, Switzerland at 22 sites in 7 countries.
Trial summary
This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR) provides better Quality of Life (QoL) with respect to long-term (24 months) physical well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing mastectomy or nipple-sparing mastectomy for prevention… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Reconstruction, Implant-Based Breast Reconstruction (IBBR)
- What is being tested?
- pre-pectoral IBBR and sub-pectoral IBBR
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 382 participants
- Where
- 22 sitesin 7 countries
- Study dates
- 28 Jul 2020to Feb 2033
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent according to ICH/GCP regulations prior to any trial specific procedures
- Patients undergoing NSM or SSM and IBBR in the therapeutic or risk-reducing Setting
- Ability to complete the Quality of Life questionnaires
Who cannot join
- No indication for IBBR according to clinical judgment of the treating surgeon
- Skin flaps inadequate for pre-pectoral IBBR.
Trial locations and contacts
22 sites in 7 countries.
22 sites in 7 countries
Switzerland9 sites
Klinik Hirslanden Brustzentrum Aarau
Aarau, 5000
Kantonsspital Aarau AG
Aarau, 5001
University Hospital Basel, Division of Breast Surgery
Basel, 4031
Universitätsklinik für Plastische- und Handchirurgie, Inselspital
Bern, 3010
Lindenhof Bern
Bern, 3011
Kantonsspital Frauenfeld
Frauenfeld, 8501
Gesundheitszentrum Fricktal
Rheinfelden, 4310
Ospedale Regionale di Lugano
Viganello, 6962
Brust-Zentrum Zürich
Zurich, 8008
Germany4 sites
Evangelisches Krankenhaus BETHESDA zu Duisburg GmbH, Klinik für Frauenheilkunde, Geburtshilfe, Gynäkologische Onkologie & Senologie
Duisburg
KEM | Evang. Kliniken Essen-Mitte
Essen, 45136
Universitätsklinikum Heidelberg
Heidelberg, 69120
Landesfrauenklinik, Senologie und Brustzentrum
Wuppertal
Sweden3 sites
Capio S:t Görans Hospital
Stockholm, 11281
Södersjukhuset
Stockholm, 11281
Karolinska University Hospital
Stockholm, 17176
Austria2 sites
Universitätsklinik für Frauenheilkunde und Geburtshilfe
Salzburg, 5020
Medizinische Universität Wien
Vienna, 1090
Italy2 sites
Universitario "Agostino Gemelli" di Roma, Unità Operativa di Chirurgia Senologica
Roma
Ospedale Santa Chiara, Breast Surgical Oncology/Oncoplastic Surgery. Breast Center
Trento
United States1 site
Brigham and Women's Hospital Harvard Medical School
Boston, Massachusetts, 02115
About this study
Official title: Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy (OPBC-02/ PREPEC): a Pragmatic, Multicenter, Randomized, Superiority Trial
This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR) provides better Quality of Life (QoL) with respect to long-term (24 months) physical well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing mastectomy or nipple-sparing mastectomy for prevention or treatment of breast cancer.
Read the detailed description
This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR) provides better Quality of Life (QoL) with respect to long-term (24 months) physical well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing mastectomy or nipple-sparing mastectomy for prevention or treatment of breast cancer.The aim is to adhere to standard of care as much as possible to follow the pragmatic trial design to generate data that are applicable to today's practice. Therefore, surgeons are allowed to use their preferred Acellular Dermal Matrix (ADM), synthetic meshes, expanders and implants, thereby offering practitioners considerable leeway in deciding how to perform the procedure. For the same reason, both the one- and two-staged IBBR approaches are allowed when studying pre- versus sub-pectoral IBBR.
- Being tested
- pre-pectoral IBBR, sub-pectoral IBBR
- Keywords
- skin-sparing mastectomy (SSM), nipple-sparing mastectomy (NSM), immediate breast reconstruction, pre-pectoral breast implant, sub-pectoral breast implant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
pre-pectoral IBBRProcedure or surgery
The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.
sub-pectoral IBBRProcedure or surgery
The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.
| Study group | Role | What they receive |
|---|---|---|
| pre-pectoral IBBR | Active comparator | Not described Receives: Procedure: pre-pectoral IBBR |
| sub-pectoral IBBR | Active comparator | Not described Receives: Procedure: sub-pectoral IBBR |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in BREAST-Q scale
compare the Quality of Life (QoL) with respect to long-term physical well-being (chest) after pre-pectoral or sub-pectoral IBBR. The BREAST-Q module specific to breast reconstruction version 2.0 consists of 13 independent scales covering health-related QoL domains and satisfaction domains. Each scale is scored to generate a numerical score on a scale from 0 (worst) to 100 (best).
Measured: within 24 months after mastectomy (screening, day 10, and months 1, 6, 12 and 24)
Change in EQ-5D-5L questionnaire
The 5-level version of the EQ-5D (EQ-5D-5L) consists of the EQ-5D descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/Depression (5 answer levels each: no problems, slight problems, moderate problems, severe problems and extreme problems), resulting in a 1-digit number that expresses the level for that dimension. The digits for each dimension are combined into a 5-digit number that describes the patient's health state and is subsequently converted into a preference-based quality of life weight (utility) using an algorithm derived from population-based studies. In addition, patients are asked to rate their health on a vertical visual analogue scale (EQ VAS), where the anchors are labelled with 'The best health you can imagine' and 'The worst health you can imagine'.
Measured: within 24 months after mastectomy (screening, day 10, and months 1, 6, 12 and 24)
Secondary outcomes (13)
loss of expander or implant
compare the safety of pre-pectoral and sub-pectoral IBBR, in terms of loss of expander or implant. Loss of expander or implant is defined as an unplanned surgical removal of expander/implant with or without immediate replacement.
Measured: within 24 months of undergoing mastectomy and immediate reconstruction
surgical complications
compare the safety of pre-pectoral and sub-pectoral IBBR, in terms of surgical complications. The complications include: Wound dehiscence, Haematoma, Seroma, Implant/expander exposure/Extrusion, Implant/Expander rotation/malpositioning, Infection, Mastectomy skin flap necrosis, Capsular contraction, Lymphedema
Measured: within 24 months of undergoing mastectomy and immediate reconstruction
thromboembolic events
compare the safety of pre-pectoral and sub-pectoral IBBR, in terms of thromboembolic events according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Measured: within 24 months of undergoing mastectomy and immediate reconstruction
patient satisfaction
compare patient satisfaction after pre-pectoral or sub-pectoral IBBR
Measured: over 24 months since mastectomy
animation deformity
compare animation deformity after pre-pectoral or sub-pectoral IBBR by using pictures from before and 24 months after the mastectomy
Measured: before and 24 months after the mastectomy
capsular contracture
compare capsular contracture after pre-pectoral or sub-pectoral IBBR by using pictures from before and 24 months after the mastectomy
Measured: before and 24 months after the mastectomy
aesthetic results
compare aesthetic results after pre-pectoral or sub-pectoral IBBR assessed by photographs of the breast taken in a standardized way. They will be evaluated by an experienced investigator who is blinded for group assignment. The blinded outcome assessment team will be trained to enter data for the two most widely used semi-automatic software for objective aesthetic evaluation, the 'Breast Cancer Conservative Treatment cosmetic results' (BCCT.core)
Measured: before and 24 months after the mastectomy
Recurrence-free survival (RFS)
RFS is defined as the time from randomization until the first documentation of any of the following events: local-regional occurrence or recurrence of invasive disease or ductal carcinoma in situ (DCIS), distant breast cancer metastasis, or death from any cause.
Measured: until 10 years after mastectomy and IBBR.
aesthetic results evaluated by patients
evaluated by patients using a four point scale: excellent, good, regular, bad.
Measured: at baseline and after 24 months
total number of operative procedures
assess the burden on patients by total number of operative procedures
Measured: until 24 months after mastectomy
length of hospital stay (index hospitalization and overall)
length of hospital stay (index hospitalization and overall) following randomization until discharge and the cumulative number of days the patient was hospitalized
Measured: until 24 months after randomization
total number of outpatient visits at the trial site and the emergency department
assess the burden on patients by total number of outpatient visits at the trial site and the emergency department
Measured: from admission for mastectomy until 24 months after randomization
aesthetic results evaluated by local physicians
evaluated by local physicians using a four point scale: excellent, good, regular, bad.
Measured: at baseline and after 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2020
- Study start28 Jul 2020
- Primary completionMay 2025 (estimated)
- Study completionFeb 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Breast ReconstructionStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study will objectively assess the results and complication of two surgical techniques and thus provide evidence to assess whether there are differences between these techniques.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 382 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Collaborators
- Swiss National Science Foundation
- Responsible party
- Sponsor
- Investigators
- Walter Weber, Prof. Dr. med, Principal investigator, Division of Breast Surgery, University Hospital Basel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04293146
- Sponsor's protocol ID
- 2020-00256; ch18Weber4
- Acronym
- OPBC-02PREPEC
- Status last verified
- Dec 2024
- First submitted
- 21 Feb 2020
- Last updated
- 13 Dec 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kappos EA, Schulz A, Regan MM, Moffa G, Harder Y, Ribi K, Potter S, Pusic AL, Fehr MK, Hemkens LG, Holzbach T, Farhadi J, Simonson C, Knauer M, Verstappen R, Bucher HC, Zwahlen D, Zimmermann F, Schwenkglenks M, Mucklow R, Shaw J, Bjelic-Radisic V, Chiorescu A, Chun YS, Farah S, Xiaosong C, Nigard L, Kuemmel S, Reitsamer R, Hauschild M, Fulco I, Tausch C, Fischer T, Sarlos D, Constantinescu MA, Lupatsch JE, Fitzal F, Heil J, Matrai Z, de Boniface J, Kurzeder C, Haug M, Weber WP. Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. BMJ Open. 2021 Sep 2;11(9):e045239. doi: 10.1136/bmjopen-2020-045239.
PubMed 34475143
Study at a glance
From the registry record, last updated by the sponsor on 13 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy (OPBC-02/ PREPEC): a Pragmatic, Multicenter, Randomized, Superiority Trial
- ClinicalTrials.gov ID
- NCT04293146
- Acronym / sponsor ID
- OPBC-02PREPEC / 2020-00256; ch18Weber4
- Keywords
- skin-sparing mastectomy (SSM), nipple-sparing mastectomy (NSM), immediate breast reconstruction, pre-pectoral breast implant, sub-pectoral breast implant
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 382 participants (actual)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Collaborators
- Swiss National Science Foundation
- Study start
- 28 Jul 2020 (actual)
- Primary completion
- May 2025 (estimated)
- Study completion
- Feb 2033 (estimated)
- First posted
- 3 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR) provides better Quality of Life (QoL) with respect to long-term (24 months) physical well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing mastectomy or nipple-sparing mastectomy for prevention or treatment of breast cancer.
Detailed description
This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR) provides better Quality of Life (QoL) with respect to long-term (24 months) physical well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing mastectomy or nipple-sparing mastectomy for prevention or treatment of breast cancer.The aim is to adhere to standard of care as much as possible to follow the pragmatic trial design to generate data that are applicable to today's practice. Therefore, surgeons are allowed to use their preferred Acellular Dermal Matrix (ADM), synthetic meshes, expanders and implants, thereby offering practitioners considerable leeway in deciding how to perform the procedure. For the same reason, both the one- and two-staged IBBR approaches are allowed when studying pre- versus sub-pectoral IBBR.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- The study will objectively assess the results and complication of two surgical techniques and thus provide evidence to assess whether there are differences between these techniques.
| Arm | Type | Receives |
|---|---|---|
| pre-pectoral IBBR | Active comparator | Procedure: pre-pectoral IBBR |
| sub-pectoral IBBR | Active comparator | Procedure: sub-pectoral IBBR |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Written informed consent according to ICH/GCP regulations prior to any trial specific procedures
- Patients undergoing NSM or SSM and IBBR in the therapeutic or risk-reducing Setting
- Ability to complete the Quality of Life questionnaires
Key exclusion criteria (2 listed)
- No indication for IBBR according to clinical judgment of the treating surgeon
- Skin flaps inadequate for pre-pectoral IBBR.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| pre-pectoral IBBRThe breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle. | Procedure or surgery | pre-pectoral IBBR |
| sub-pectoral IBBRThe breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle. | Procedure or surgery | sub-pectoral IBBR |
Primary outcome
Change in BREAST-Q scale
Time frame: within 24 months after mastectomy (screening, day 10, and months 1, 6, 12 and 24)
compare the Quality of Life (QoL) with respect to long-term physical well-being (chest) after pre-pectoral or sub-pectoral IBBR. The BREAST-Q module specific to breast reconstruction version 2.0 consists of 13 independent scales covering health-related QoL domains and satisfaction domains. Each scale is scored to generate a numerical score on a scale from 0 (worst) to 100 (best).
Change in EQ-5D-5L questionnaire
Time frame: within 24 months after mastectomy (screening, day 10, and months 1, 6, 12 and 24)
The 5-level version of the EQ-5D (EQ-5D-5L) consists of the EQ-5D descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/Depression (5 answer levels each: no problems, slight problems, moderate problems, severe problems and extreme problems), resulting in a 1-digit number that expresses the level for that dimension. The digits for each dimension are combined into a 5-digit number that describes the patient's health state and is subsequently converted into a preference-based quality of life weight (utility) using an algorithm derived from population-based studies. In addition, patients are asked to rate their health on a vertical visual analogue scale (EQ VAS), where the anchors are labelled with 'The best health you can imagine' and 'The worst health you can imagine'.
13 secondary outcomes
loss of expander or implant
Time frame: within 24 months of undergoing mastectomy and immediate reconstruction
surgical complications
Time frame: within 24 months of undergoing mastectomy and immediate reconstruction
thromboembolic events
Time frame: within 24 months of undergoing mastectomy and immediate reconstruction
patient satisfaction
Time frame: over 24 months since mastectomy
animation deformity
Time frame: before and 24 months after the mastectomy
capsular contracture
Time frame: before and 24 months after the mastectomy
aesthetic results
Time frame: before and 24 months after the mastectomy
Recurrence-free survival (RFS)
Time frame: until 10 years after mastectomy and IBBR.
aesthetic results evaluated by patients
Time frame: at baseline and after 24 months
total number of operative procedures
Time frame: until 24 months after mastectomy
length of hospital stay (index hospitalization and overall)
Time frame: until 24 months after randomization
total number of outpatient visits at the trial site and the emergency department
Time frame: from admission for mastectomy until 24 months after randomization
aesthetic results evaluated by local physicians
Time frame: at baseline and after 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Dec 2024.
- Derived from this study: PubMed 34475143Kappos EA, Schulz A, Regan MM, Moffa G, Harder Y, Ribi K, Potter S, Pusic AL, Fehr MK, Hemkens LG, Holzbach T, Farhadi J, Simonson C, Knauer M, Verstappen R, Bucher HC, Zwahlen D, Zimmermann F, Schwenkglenks M, Mucklow R, Shaw J, Bjelic-Radisic V, Chiorescu A, Chun YS, Farah S, Xiaosong C, Nigard L, Kuemmel S, Reitsamer R, Hauschild M, Fulco I, Tausch C, Fischer T, Sarlos D, Constantinescu MA, Lupatsch JE, Fitzal F, Heil J, Matrai Z, de Boniface J, Kurzeder C, Haug M, Weber WP. Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. BMJ Open. 2021 Sep 2;11(9):e045239. doi: 10.1136/bmjopen-2020-045239.
- Individual participant dataSharing planned: No
Related trials for Breast Reconstruction
Recruiting
ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction
Breast Cancer, Cancer of the Breast
RecruitingObservational study
The Study is an Observational Post-market Follow-up Program to Evaluate Long Term (5 Years) Safety of Mentor Breast Implants in Chinese Population
Breast Augmentation, Mammaplasty
Active, not recruiting
A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction
Breast Reconstruction, Revision Breast Reconstruction
Active, not recruiting
Memory Gel and Shape Combined Cohort
Primary Breast Augmentation, Primary Breast Reconstruction
Not yet recruiting
Impact of Intraoperative Neurotization on Sensory Recovery of the Nipple and Breast Skin in Patients Undergoing Nipple Sparing Mastectomy With Immediate Implant-Based Reconstruction: NERSENSE, Prospective Randomized Control Study
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Walter Weber, Prof. Dr. med principal investigator
Division of Breast Surgery, University Hospital Basel
22 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing pre-pectoral IBBR and sub-pectoral IBBR in people with Breast Reconstruction and Implant-Based Breast Reconstruction (IBBR), run by University Hospital, Basel, Switzerland at 22 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 22 sites in Switzerland, Germany, Sweden, Austria, Italy and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in BREAST-Q scale (time frame: within 24 months after mastectomy (screening, day 10, and months 1, 6, 12 and 24)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04293146, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2024.